BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meng N, Gao X, Yan W, Wang M, Liu P, Lu XD, Zhang SJ, Lu YQ, Tang WX. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci. 2015;35:230-234. [PMID: 25877357 DOI: 10.1007/s11596-015-1416-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tschöpe C, Cooper LT, Torre-Amione G, Van Linthout S. Management of Myocarditis-Related Cardiomyopathy in Adults. Circ Res 2019;124:1568-83. [PMID: 31120823 DOI: 10.1161/CIRCRESAHA.118.313578] [Cited by in Crossref: 70] [Cited by in F6Publishing: 37] [Article Influence: 35.0] [Reference Citation Analysis]
2 Van Linthout S, Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy. Curr Opin Cardiol 2018;33:325-33. [PMID: 29528906 DOI: 10.1097/HCO.0000000000000515] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
3 Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016;89:24-31. [PMID: 27004022 DOI: 10.15386/cjmed-554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
5 Schultheiss HP, Bock T, Pietsch H, Aleshcheva G, Baumeier C, Fruhwald F, Escher F. Nucleoside Analogue Reverse Transcriptase Inhibitors Improve Clinical Outcome in Transcriptional Active Human Parvovirus B19-Positive Patients. J Clin Med 2021;10:1928. [PMID: 33946917 DOI: 10.3390/jcm10091928] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Lou X, Hou Y, Cao H, Zhao J, Zhu F. Clinical significance of decoy receptor 3 upregulation in patients with hepatitis B and liver fibrosis. Oncol Lett 2018;16:1147-54. [PMID: 30061940 DOI: 10.3892/ol.2018.8762] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Van Linthout S, Elsanhoury A, Klein O, Sosnowski M, Miteva K, Lassner D, Abou-El-Enein M, Pieske B, Kühl U, Tschöpe C. Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity. ESC Heart Fail 2018;5:818-29. [PMID: 30099854 DOI: 10.1002/ehf2.12341] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
8 Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunol Lett 2017;190:206-12. [PMID: 28827021 DOI: 10.1016/j.imlet.2017.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]